References
- Messenger AG. Scaling disorders of the scalp. In: Burns T, Breathnach S, Cox N, Griffiths C, eds. Rook’s textbook of dermatology. 8th ed. Oxford: Wiley-Blackwell; 2010:ch 66
- Plewig G, Jansen T. Seborrheic dermatitis. In: Wolff K, Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ, eds. Fitzpatrick’s dermatology in general medicine. 7th ed. New York: McGraw-Hill; 2008:219–225
- Ettler J, Wetter DA, Pittelkow MR. Pityriasis amiantacea: a distinctive presentation of psoriasis associated with tumour necrosis factor-α inhibitor therapy. Clin Exp Dermatol 2012;37:639–641
- Sinha R, Edmonds K, Newton-Bishop JA, et al. Cutaneous adverse events associated with vemurafenib in patients with metastatic melanoma: practical advice on diagnosis, prevention and management of the main treatment-related skin toxicities. Br J Dermatol 2012;167:987–994
- Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507–2516
- Macdonald JB, Macdonald B, Golitz LE, et al. Cutaneous adverse effects of targeted therapies. Part II: inhibitors of intracellular molecular signaling pathways. J Am Acad Dermatol 2015;72:221–236
- Abdel-Hamid IA, Agha SA, Moustafa YM, El-Labban AM. Pityriasis amiantacea: a clinical and etiopathologic study of 85 patients. Int J Dermatol 2003;42:260–264
- Lacouture ME, Duvic M, Hauschild A, et al. Analysis of dermatologic events in vemurafenib-treated patients with melanoma. Oncologist 2013;18:314–322
- Belum VR, Rosen AC, Jaimes N, et al. Clinico-morphological features of BRAF inhibition-induced proliferative skin lesions in cancer patients. Cancer 2015;121:60–68
- Sambrano BL, Riddel CE, Chon SY. Eruptive milia secondary to vemurafenib. J Am Acad Dermatol 2013;69:e258–e260